ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Animal models"

  • Abstract Number: 3190 • 2015 ACR/ARHP Annual Meeting

    Netrin-1 and Its Receptor Unc5b Are Novel Targets for the Treatment of Inflammatory Arthritis

    Aranzazu Mediero1, Tuere Wilder2 and Bruce Cronstein3, 1Medicine, Divison of Translational Medicine, NYU School of Medicine, New York City, NY, 2Dept of Med, Div of Rheum, NYU School of Medicine, New York, NY, 3Medicine, Division of Rheumatology, NYU School of Medicine, NEW YORK, NY

    Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation and destruction of the joints and some extra-articular tissues. Netrin-1 is a laminin-like…
  • Abstract Number: 1034 • 2015 ACR/ARHP Annual Meeting

    Immunomodulation By a Second-Generation Peptidyl Arginine Deiminase Inhibitor Abrogates Collagen-Induced Arthritis in a Therapeutic Protocol

    Anne-Marie Quirke1, Joanna Kawalkowska2, Fatemeh Ghari3, Venkataraman Subramaniam4, Paul Thompson5, Richard O. Williams1, Nick La Thangue3 and Patrick J. Venables1, 1Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, 2Kennedy Institute for Rheumatology, University of Oxford, Oxford, United Kingdom, 3Department of Oncology, University of Oxford, Oxford, United Kingdom, 4Biochemistry and Molecular Pharmacology, University of Massachusetts, Worcester, MA, 5University of Massachusetts, Worcester, MA

    Background/Purpose: Citrullination is a post translational modification of arginine catalysed by peptidyl arginine deiminases (PADs) and may be important in generating pathogenic autoantibodies to citrullinated…
  • Abstract Number: 2555 • 2015 ACR/ARHP Annual Meeting

    14-3-3η As a Novel RA Drug Target: Anti-14-3-3η Monoclonal Antibody Delays the Onset and Mitigates the Severity of Arthritis in CIA Mice

    Abedelnasser Abulrob1, Mario Mercier1, Slavisa Corluka1, Roger MacKenzie1, Shalini Raphael1, Sara Michienzi2, Jane Savill2, Yuan Gui2, Walter Maksymowych3 and Anthony Marotta2, 1National Research Council of Canada, Ottawa, ON, Canada, 2Augurex Life Sciences Corp., Vancouver, BC, Canada, 3Department of Medicine, University of Alberta, Edmonton, AB, Canada

    Background/Purpose: As an extracellular ligand, 14-3-3η potently and concentration-dependently upregulates the expression of multiple factors including TNFα, IL-6, and RANKL and its clinical detection is…
  • Abstract Number: 3191 • 2015 ACR/ARHP Annual Meeting

    Siglec9 Suppresses Arthritis in Collagen-Induced Mice Model and Inhibits M1 Activation of RAW264.7 Macrophages

    Takuya Matsumoto1, Nobunori Takahashi1, Toshihisa Kojima1 and Naoki Ishiguro2, 1Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, 2Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan

    Background/Purpose: Siglecs (Sialic acid-binding immunoglobulin-type lectins) are type1 transmembrane proteins and expressed on cell surface of various immunocytes. Siglec9 is a member of CD33 related…
  • Abstract Number: 1053 • 2015 ACR/ARHP Annual Meeting

    Phosphatidylinositol-3-Kinase Delta Pathway a Novel Therapeutic Target for Sjogren’s Syndrome

    Saba Nayar1, Joana Campos1, Christopher Buckley1, Rodger Allen2, W.A. Fahy2, Andrew Payne2 and Francesca Barone1, 1University of Birmingham, Rheumatology Research Group, Birmingham, United Kingdom, 2UCB Pharma, Slough, United Kingdom

    Background/Purpose: Sjögren’s syndrome (SS) is a chronic autoimmune disease characterized by B cell hyper-activation and exocrine gland infiltration that results in loss of glandular function,…
  • Abstract Number: 2557 • 2015 ACR/ARHP Annual Meeting

    Comparable Therapeutic Potential of Umbilical Cord Mesenchymal Stem Cells in Collagen Induced Arthritis with Anti-Tumor Necrosis Factor or Anti-CD20

    Yue Sun, Wei Kong, Weiwei Chen, Genhong Yao, Xuebing Feng and Lingyun Sun, Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China

    Background/Purpose: Tremendous progress has been made in the development of non-conventional therapies for rheumatoid arthritis (RA). Mesenchymal stem cells (MSC) present multiple immunosuppressive capacities and…
  • Abstract Number: 3192 • 2015 ACR/ARHP Annual Meeting

    KCa3.1 Ion Channel in the Pathogenesis of Rheumatoid Arthritis: KCa3.1-/- Mice Do Not Develop CIA

    Siba Raychaudhuri1, Smriti K. Raychaudhuri2 and Heike Wulff3, 1Med/Rheumatology, Univ California Davis/VA Sacramento, Davis, CA, 2Rheumatology/Immunology, VA Sacramento Medical Center, Davis, CA, 3Pharmacology, UC Davis School of Medicine, Davis, CA

    Background/Purpose: KCa3.1 is a Ca2+-activated K+ channel that modulates Ca2+-dependent signaling processes such as activation and cellular proliferation. KCa3.1 is expressed in CCR7+ naïve and…
  • Abstract Number: 1106 • 2015 ACR/ARHP Annual Meeting

    Efficacy of Abbv-105, a Selective and Irreversible Inhibitor of Bruton’s Tyrosine Kinase (BTK), in Multiple Models of Inflammation

    Christian Goess1, Candace Graff2, Ting Ting Zhang2, Gregory Preston2, Richard McCarthy1, Matthew Perham1, Jacqueline Loud1, Christopher M. Harris1, Sara Murdock1, Erik Sampson3, Michael Hoemann4, Michael Friedman4, Robert Talanian3, Jeremy Edmunds4 and Andrew Long1, 1Immunology Pharmacology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, 2DMPK, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, 3AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, 4Chemistry, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA

    Background/Purpose: Bruton’s Tyrosine Kinase (BTK) is a non-receptor tyrosine kinase required for intracellular signaling pathways downstream of several key immunoreceptors, including the B cell receptor,…
  • Abstract Number: 2558 • 2015 ACR/ARHP Annual Meeting

    The Role of Leukocyte Associated Immunoglobulin-like Receptor-1 (LAIR-1) in Collagen-Induced Arthritis

    Seunghyun Kim1, John E. Coligan2, Jeoung-Eun Park3, John M. Stuart4, Andrew Kang5 and Linda Myers5, 1Rheumatology, University of Tennessee Health Science Center, Memphis, TN, 2NIH, Bethesda, MD, 3University of Tennessee, Memphis, TN, 4University of Tennessee/Veterans Affairs, Memphis, TN, 5University of Tennessee Health Science Center, Memphis, TN

    Background/Purpose: Several observations implicate a critical role for T cell dysregulation as a central problem in RA.  We present a method for suppressing T cell…
  • Abstract Number: 1123 • 2015 ACR/ARHP Annual Meeting

    Regulatory B Cells Regulate Skin and Lung Fibrosis and Immunological Abnormalities in a Topoisomerase I and Complete Freund’s Adjuvant-Induced Scleroderma Model Via an Antigen-Specific Manner

    Ayumi Yoshizaki1, Takashi Taniguchi1, Kouki Nakamura1, Ryosuke Saigusa1, Takashi Yamashita1, Takehiro Takahashi1, Tetsuo Toyama1, Yohei Ichimura1, Yoshihide Asano2 and Shinichi Sato1, 1Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, 2University of Tokyo Graduate School of Medicine, Tokyo, Japan

    Background/Purpose: Immune cells play a critical role in systemic sclerosis (SSc). B cells have more functions than producing antibodies, including antigen-presentation, various cytokine production, and…
  • Abstract Number: 2559 • 2015 ACR/ARHP Annual Meeting

    PRO-Resolving Mediators Issued from Apoptotic CELL Efferocytosis (SUPERMAPO) Modulate Antigen Presenting CELL Properties Toward a Tolerogenic Profile: Efficacy in the Treatment of Collagen- Induced Arthritis

    Francis Bonnefoy1, Romain Vallion2, Mélanie Couturier3, Anna Daoui3, Eric Toussirot4 and Sylvain Perruche1, 1UMR1098 INSERM, EFS Bourgogne Franche Comté, Besançon, France, 2INSERM UMR 1098, EFS Bourgogne Franche Comté, Besançon, France, 3INSERM UMR1098, EFS Bourgogne Franche Comté, Besançon, France, 4Service de Rhumatologie, CHU J Minjoz, Besancon, France

    Background/Purpose: Pro-resolving mediators produced by macrophages eliminating apoptotic effector cells during the resolution of inflammation have been shown to stop inflammation, favor tissue repair and…
  • Abstract Number: 1173 • 2015 ACR/ARHP Annual Meeting

    G Protein Coupled Receptor Kinase 3 Regulation of Inflammatory Arthritis

    Matthew J. Billard1, Roman Timoshchenko2, D. Stephen Serafin2 and Teresa K. Tarrant3, 1Medicine, University of North Carolina, Chapel Hill, NC, 2Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC, 3Rheumatology, University of North Carolina, Chapel Hill, NC

    Background/Purpose:   Chemokine receptors are G Protein Coupled Receptor (GPCR) family members that direct cell migration, differentiation, and survival in inflammatory conditions, but neutralization strategies…
  • Abstract Number: 2560 • 2015 ACR/ARHP Annual Meeting

    The Mer Tyrosine Kinase Receptor Plays a Protective Role in Joint Inflammation By Mediating Efferocytosis

    Claire E.J. Waterborg1, Silke Beermann1, Miranda B. Bennink1, Carla V. Rothlin2, Greg Lemke3 and Fons A.J. van de Loo1, 1Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, 2Department of Immunobiology, Yale University School of Medicine, New Haven, CT, 3Molecular Neurobiology Laboratory, Salk Institute for Biological Studies, La Jolla, CA

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by a hyper-inflammatory response in synovial joints. In joints of patients with active RA, few…
  • Abstract Number: 1427 • 2015 ACR/ARHP Annual Meeting

    Analgesic Effects of the Novel Alpha-2-Delta Ligand Mirogabalin (DS-5565) in Experimental Animal Models of Fibromyalgia

    Yuki Domon1, Naohisa Arakawa1, Shun-ichi Yasuda2, Kensuke Saeki2, Mayumi Kano2, Masami Kato2 and Yutaka Kitano1, 1Biological Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan, 2Hashima Laboratory, Nihon Bioresearch Inc., Gifu, Japan

    Background/Purpose: Mirogabalin (DS-5565) is a novel ligand of the α2δ subunit of voltage-gated calcium channels. Mirogabalin possesses unique binding characteristics to α2δ subunits, and potent…
  • Abstract Number: 2563 • 2015 ACR/ARHP Annual Meeting

    Immune Regulation By Migrating Mesenchymal Stem Cells Ameliorate Inflammatory Arthritis in Mice

    Seung Min Jung, Yoojun Nam and Ji Hyeon Ju, Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea

    Background/Purpose: Mesenchymal stem cells (MSCs) function as immune regulators in inflammatory conditions. However, it is unclear how to control local inflammation by systemically administered MSCs. We…
  • « Previous Page
  • 1
  • …
  • 11
  • 12
  • 13
  • 14
  • 15
  • …
  • 25
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology